Loading...
SWTX logo

SpringWorks Therapeutics, Inc.NasdaqGS:SWTX Stok Raporu

Piyasa Değeri US$3.5b
Hisse Fiyatı
n/a
1Y26.0%
7D0.04%
1D0.02%
Portföy Değeri
​
Görünüm

SpringWorks Therapeutics, Inc.

NasdaqGS:SWTX Stok Raporu

Piyasa değeri: US$3.5b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

SpringWorks Therapeutics (SWTX) Hisse Özeti

Ticari aşamada bir biyofarmasötik şirketi olan SpringWorks Therapeutics, Inc. nadir hastalıklar ve kanserden muzdarip yetersiz hizmet alan hasta popülasyonları için ilaç geliştirme ve ticarileştirme faaliyetlerinde bulunmaktadır. Daha fazla detay

Ödüller

Kazançların yılda 62.07% oranında artması öngörülüyor

Risk Analizi

Risk kontrollerimizden SWTX için herhangi bir risk tespit edilmedi.

SWTX Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

SpringWorks Therapeutics, Inc. Rakipler

Fiyat Geçmişi ve Performans

Hisse fiyatlarındaki yükseliş, düşüş ve değişimlerin özeti SpringWorks Therapeutics
Tarihsel hisse senedi fiyatları
Güncel Hisse FiyatıUS$46.99
52 Haftanın En Yüksek SeviyesiUS$62.00
52 Haftanın En Düşük SeviyesiUS$28.21
Beta0.70
1 Aylık Değişim0.69%
3 Aylık Değişim9.10%
1 Yıllık Değişim26.05%
3 Yıllık Değişim68.66%
5 Yıllık Değişim13.23%
Halka arzdan bu yana değişim107.64%

Son Haberler & Güncellemeler

Recent updates

Seeking Alpha • Apr 29

SpringWorks: Acquired By Merck KGaA Based On Rare Tumor Targeting Drugs Like OGSIVEO

Summary Merck KGaA agreed to acquire SpringWorks Therapeutics for $47 per share in cash or for $3.9 billion; the acquisition brings in drugs of OGSIVEO and GOMEKLI to big pharma's pipeline. Expansion opportunities for OGSIVEO include potential European approval for desmoid tumors and trials for relapsed/refractory ovarian granulosa cell tumors. GOMEKLI's approval for NF1-PN patients and ongoing European review further enhance SpringWorks' pipeline value. GOMEKLI is also being explored in a phase 1/2 open-label study to treat pediatric and adult patients with low-grade gliomas. Read the full article on Seeking Alpha
Analiz Makalesi • Mar 12

SpringWorks Therapeutics, Inc.'s (NASDAQ:SWTX) Shares Climb 26% But Its Business Is Yet to Catch Up

The SpringWorks Therapeutics, Inc. ( NASDAQ:SWTX ) share price has done very well over the last month, posting an...
Seeking Alpha • Mar 11

SpringWorks Therapeutics: Promising Launches, Expanding Pipeline, And M&A Buzz

Summary SpringWorks Therapeutics portfolio features Ogsiveo for desmoid tumors and Gomekli for NF1‑plexiform neurofibromas. In fact, Ogsiveo’s revenues alone reached $172 million in 2024, supported by orphan drug designations in the US and EU. Similarly, Gomekli is the first FDA-approved MEK inhibitor for NF1‑plexiform neurofibromas, which targets both adults and children. SpringWorks is also working on new potential indications for its IP portfolio while running additional trials and even attracting M&A interest from larger players. In my view, SWTX stock’s valuation has a bit of premium embedded in it, but it looks well deserved. In fact, I believe it’s a good speculative “Buy” at these levels. Read the full article on Seeking Alpha
Seeking Alpha • Jan 13

SpringWorks: PDUFA Review Date Could Lead To Next Approved Pipeline Candidate

Summary SpringWorks has shown strong revenue growth with OGSIVEO, achieving a 23% increase from Q2 of 2024 to Q3 of 2024, and potential EMA approval if it could boost sales further. Mirdametinib, a MEK inhibitor for NF1-PN, has a PDUFA date of February 28th of 2025, and could unlock significant shareholder value if approved. Results from phase 1b study using brimarafenib to treat patients with MAPK mutant solid tumors are expected to be released in the 2nd half of 2025. The company has $498 million in cash as of September 30th of 2024, which is sufficient to fund its operations into the first half of 2026. Read the full article on Seeking Alpha
Seeking Alpha • Dec 31

SpringWorks: With Catalyst On The Horizon And Growing Sales, 2025 Looks Great

Summary SpringWorks Therapeutics shows promising growth with their first approved drug and an imminent second approval for mirdametinib in NF1 treatment. SWTX's financials reveal strong cash reserves and growing sales, though they remain unprofitable, with a net loss of $53.5 million in Q3 2024. Strengths include sustained sales growth and potential back-to-back drug approvals, but risks involve market competition and aggressive goal setting. Despite current valuation concerns, SWTX's fundamentals and potential sales growth justify a "Buy" sentiment for the stock. Read the full article on Seeking Alpha
Seeking Alpha • Dec 15

Tarsus Pharmaceuticals & SpringWorks Therapeutics: Jonathan Faison's Top 2 Picks

Summary Jonathan Faison runs the ROTY Biotech Community. Why he's high on Tarsus Pharmaceuticals and his #1 holding, SpringWorks Therapeutics. SpringWorks Therapeutics has promising data with multiple launches planned for next year. Tarsus Pharmaceuticals' lead drug shows strong launch metrics, suggesting significant upside potential despite its current market cap. Read the full article on Seeking Alpha
Analiz Makalesi • Nov 15

Here's What Analysts Are Forecasting For SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) After Its Third-Quarter Results

It's been a pretty great week for SpringWorks Therapeutics, Inc. ( NASDAQ:SWTX ) shareholders, with its shares surging...
Seeking Alpha • Nov 04

SpringWorks Therapeutics Merits A Speculative Buy

Summary Since we last visited SpringWorks Therapeutics, Inc. in the summer of 2023, the company has garnered its first FDA approval. That drug has seen encouraging initial sales, and management recently submitted a marketing application for a second candidate. The stock has pulled back recently, even as SpringWorks has funding to get the company to profitability in the years ahead. An updated analysis around SpringWorks Therapeutics follows in the paragraphs below. Read the full article on Seeking Alpha
Seeking Alpha • Aug 07

SpringWorks Therapeutics: Rising On A Strong Post-Launch Quarter, Now Justified As A Buy

Summary SWTX's market confidence has increased post-launch, with $40.2 million in product revenue and $19.5 million in collaboration revenue in the first quarter. Nirogacestat approval for desmoid tumors and potential approval for mirdametinib in 2025 position SWTX well for growth. SWTX's strong commercial execution and expanding product portfolio indicate the potential for profitability and market appreciation. Read the full article on Seeking Alpha
Analiz Makalesi • May 11

Need To Know: Analysts Are Much More Bullish On SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Revenues

SpringWorks Therapeutics, Inc. ( NASDAQ:SWTX ) shareholders will have a reason to smile today, with the analysts making...
Analiz Makalesi • May 03

We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Seeking Alpha • Apr 25

SpringWorks Therapeutics: Newly Commercial Stage, Fully Valued Biotech Means Steer Clear

Summary SpringWorks Therapeutics has received FDA approval for Nirogacestat, marking its entry into the commercial stage biotech industry. The company is now facing the challenge of successfully commercializing its therapy. With rapidly growing losses and its hefty market cap SpringWorks Therapeutics is a "Hold". Read the full article on Seeking Alpha
Seeking Alpha • Apr 19

SpringWorks Therapeutics: Multiple Opportunities, But No Sure-Fire Winners

Summary SpringWorks Therapeutics received FDA approval for its oral gamma secretase inhibitor Ogsiveo for the treatment of desmoid tumors in November last year. Ogsiveo is the first therapy approved for desmoid tumors, with a market opportunity estimated at $2.2 billion. Sales in Q4 2023 were just $5m, however, while net loss was $325m. Ogsiveo could win approval in Europe and also in a new indication Ovarian Granulosa Cell Tumors, opening up larger markets. A second candidate, mirdametinib, may be on track for approval in the rare disease NF-1, and is being evaluated in oncology settings also - as is nirogacestat (Ogsiveo). With more early stage programs, and multiple catalysts in play, some may feel SpringWorks's shares - up over 70% on a 12-months basis - can realise further upside. There is alot of uncertainty, however, which I why I maintain a "hold" rating. Read the full article on Seeking Alpha
Analiz Makalesi • Sep 20

We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analiz Makalesi • Jun 07

We're Not Very Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analiz Makalesi • Feb 22

We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analiz Makalesi • Nov 09

Here's Why We're Not Too Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Hissedar Getirileri

SWTXUS BiotechsUS Pazar
7D0.04%7.5%-2.5%
1Y26.0%40.9%19.0%

Getiri vs. Endüstri: SWTX geçen yıl % 40.9 oranında getiri sağlayan US Biotechs sektörünü aştı.

Getiri vs Piyasa: SWTX geçen yıl % 19 oranında getiri sağlayan US Piyasasını aştı.

Fiyat Oynaklığı

Is SWTX's price volatile compared to industry and market?
SWTX volatility
SWTX Average Weekly Movement6.4%
Biotechs Industry Average Movement10.5%
Market Average Movement7.3%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.1%

İstikrarlı Hisse Senedi Fiyatı: SWTX son 3 ayda US piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: SWTX 'nin haftalık oynaklığı ( 6% ) son bir yıldır istikrarlı seyretti.

Şirket Hakkında

KurulduÇalışanlarCEOWeb sitesi
2017368Saqib Islamwww.springworkstx.com

Ticari aşamada bir biyofarmasötik şirketi olan SpringWorks Therapeutics, Inc. nadir hastalıklar ve kanserden muzdarip yetersiz hizmet alan hasta popülasyonları için ilaç geliştirme ve ticarileştirme faaliyetlerinde bulunmaktadır. Desmoid tümörlerin tedavisi için oral küçük moleküllü bir gama sekretaz inhibitörü olan OGSIVEO (nirogacestat) ve nörofibromatozis tip 1 ile ilişkili pleksiform nörofibromları (NF1-PN) olan iki yaş ve üzeri yetişkin ve pediatrik hastaların tedavisi için oral küçük moleküllü bir MEK1 ve MEK2 inhibitörü olan GOMEKLI (mirdametinib) sunmaktadır. Şirket ayrıca, yumurtalık kanserinin bir alt türü olan yumurtalık granüloza hücre tümörlerinin (GCT) tedavisi için monoterapi olarak Faz 2 klinik geliştirme aşamasında olan Nirogacestat'ı ve Faz 1/2 klinik çalışmasında olan düşük dereceli gliomalı pediatrik ve genç yetişkin hastaların tedavisi de dahil olmak üzere diğer MAPK aberasyonlarını barındıran katı tümörlerin tedavisi için mirdametinib'i geliştirmektedir.

SpringWorks Therapeutics, Inc. Temel Bilgiler Özeti

SpringWorks Therapeutics'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
SWTX temel i̇stati̇sti̇kler
Piyasa değeriUS$3.54b
Kazançlar(TTM)-US$253.93m
Gelir(TTM)US$219.67m
16.1x
P/S Oranı
-13.9x
F/K Oranı

SWTX aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
SWTX gelir tablosu (TTM)
GelirUS$219.67m
Gelir MaliyetiUS$14.88m
Brüt KârUS$204.80m
Diğer GiderlerUS$458.73m
Kazançlar-US$253.93m

Son Raporlanan Kazançlar

Mar 31, 2025

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)-3.37
Brüt Marj93.23%
Net Kâr Marjı-115.60%
Borç/Özkaynak Oranı0%

SWTX uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2025/07/02 11:33
Gün Sonu Hisse Fiyatı2025/06/30 00:00
Kazançlar2025/03/31
Yıllık Kazançlar2024/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları GitHub sayfamızda mevcuttur; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

SpringWorks Therapeutics, Inc. 4 Bu analistlerden 3, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
Cory KasimovEvercore ISI
Corinne JohnsonGoldman Sachs
Michael SchmidtGuggenheim Securities, LLC